Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $25.06 Consensus Price Target from Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have received an average rating of “Hold” from the twenty analysts that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $25.0588.

A number of brokerages have recently issued reports on SRPT. Zacks Research raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, July 9th. Finally, Weiss Ratings downgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently added to or reduced their stakes in SRPT. Bank of America Corp DE grew its stake in shares of Sarepta Therapeutics by 26.6% in the first quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock worth $46,695,000 after purchasing an additional 450,336 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $8,165,000. GSA Capital Partners LLP bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $1,862,000. Vanguard Group Inc. lifted its stake in Sarepta Therapeutics by 9.2% in the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after acquiring an additional 993,283 shares during the period. Finally, M&T Bank Corp bought a new stake in Sarepta Therapeutics in the fourth quarter valued at $1,794,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Up 2.9%

Shares of NASDAQ SRPT opened at $19.46 on Monday. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average of $17.58 and a 200-day moving average of $18.28. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -6.71, a PEG ratio of 0.28 and a beta of 0.23. Sarepta Therapeutics has a 12 month low of $14.68 and a 12 month high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.42. The firm had revenue of $401.25 million during the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The company’s revenue was down 34.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.02 earnings per share. Sell-side analysts expect that Sarepta Therapeutics will post 3.43 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.